Arrowhead Research Corp (NASDAQ:ARWR) a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -13.23%. On last trading day company shares ended up $12.33. Analysts mean target price for the company is $27.90. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -2.54%.
On Jun 16, 2014, Embedded system design engineers looking to upgrade their 8- and 16-bit legacy designs to a 32-bit ARM CPU can do so for less than a pack of AA batteries, thanks to a new PSoC®4 prototyping kit from Cypress Semiconductor Corp. (NASDAQ:CY). The $4 CY8CKIT-049 Prototyping Kit enables designers to leverage the powerful 32-bit ARM® Cortex™-M0 core, programmable analog and digital peripherals, and the industry-leading CapSense® capacitive touch-sensing technology of Cypress’s PSoC 4 architecture. Cypress Semiconductor Corporation (NASDAQ:CY) shares fell -0.36% in last trading session and ended the day on $10.95. Gross Margin is 46.80% and its return on assets is -3.30%. Cypress Semiconductor Corporation (NASDAQ:CY) quarterly performance is 8.42%.
ImmunoGen Inc. (NASDAQ:IMGN) a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology disclosed for the first time preclinical data for IMGN779. The data were presented at the 19th Congress of the European Hematology Association (EHA) meeting in Milan Italy (abstract# P802). IMGN779 is a novel CD33-targeting DNA-alkylating ADC that is a potential treatment for acute myeloid leukemia (AML). ImmunoGen, Inc. (NASDAQ:IMGN) shares moved up 0.45% in last trading session and was closed at $13.26, while trading in range of $13.13- $13.69. ImmunoGen, Inc. (NASDAQ:IMGN) year to date (YTD) performance is -9.61%.
Sequenom, Inc. (NASDAQ:SQNM) a life sciences company providing innovative genetic analysis solutions, and Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services, announced an agreement under which Quest will offer national access to Sequenom Laboratories’ MaterniT21™PLUS laboratory-developed test (LDT). Sequenom, Inc. (NASDAQ:SQNM) ended the last trading day at $3.06. Company weekly volatility is calculated as 3.88% and price to cash ratio as 6.33. Sequenom, Inc. (NASDAQ:SQNM) showed a positive weekly performance of 3.03%.
Limelight Networks, Inc. (NASDAQ:LLNW) a global leader in digital content delivery, announced that it has received an unsolicited offer to purchase the company from an entity that management believes is a non-credible source. Under the proposal, first reported by media outlets, then confirmed via phone and follow up email, on June 13, Tuition Build Inc. has offered to purchase and take private Limelight Networks for $644.7 million or $6.55 per share if certain unspecified financial thresholds were satisfied. Limelight Networks, Inc. (NASDAQ:LLNW) net profit margin is -32.10% and weekly performance is -1.74%. On last trading day company shares ended up $ 2.83. Analysts mean target price for the company is $2.80. Limelight Networks, Inc. (NASDAQ:LLNW) distance from 50-day simple moving average (SMA50) is 26.27%.